Literature DB >> 3621677

Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

A Rødgaard, F C Nielsen, R Djurup, F Somnier, S Gammeltoft.   

Abstract

The concentrations of IgG subclass antibodies (Ab) to acetylcholine receptor (AchR) were quantified in 36 patients with myasthenia gravis (MG) treated with pyridostigmine only, and in eight patients who underwent thymectomy, using an IgG subclass-specific immunoprecipitation assay. IgG1, IgG2, IgG3, and IgG4 subclass Ab to AchR were present in 100%, 33%, 64% and 39% of the pyridostigmine-treated patients, respectively. The concentration of IgG1 Ab increased significantly with disease severity as graded by the Osserman-Genkins classification (rs = 0.37, P less than 0.05). IgG1 and IgG3 subclass protein concentrations were significantly higher (P less than 0.0003) in the 36 pyridostigmine-treated MG patients than in 44 age- and sex-matched healthy subjects. Thymectomy induced an appreciable reduction in anti-AchR IgG1 concentration in two patients, whereas six patients showed no changes in Ab to AchR. The results support the hypothesis that binding of anti-AchR IgG1 and IgG3 on AchR in the neuromuscular junction followed by complement-mediated cell lysis or phagocytosis, may play a role in the pathogenesis of MG.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621677      PMCID: PMC1542559     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.

Authors:  A K Lefvert; K Bergström; G Matell; P O Osterman; R Pirskanen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

Review 2.  Human immunoglobulins: classes, subclasses, genetic variants, and idiotypes.

Authors:  J B Natvig; H G Kunkel
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

3.  Humoral immunity before and after thymectomy in myasthenia gravis.

Authors:  G K Scadding; A D Webster; M Ross; H C Thomas; C W Havard
Journal:  Neurology       Date:  1979-04       Impact factor: 9.910

4.  No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis.

Authors:  A D Roses; C W Olanow; M W McAdams; R J Lane
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

5.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

Review 6.  Immunology of acetylcholine receptors in relation to myasthenia gravis.

Authors:  A Vincent
Journal:  Physiol Rev       Date:  1980-07       Impact factor: 37.312

Review 7.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

8.  Acetylcholine receptor antibody in myasthenia gravis: purification and characterization.

Authors:  A K Lefvert; K Bergström
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

9.  Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations.

Authors:  R S Tindall
Journal:  Ann Neurol       Date:  1981-11       Impact factor: 10.422

10.  An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.

Authors:  J Lindstrom
Journal:  Clin Immunol Immunopathol       Date:  1977-01
View more
  36 in total

Review 1.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

4.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

Review 5.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

6.  Congenital myasthenic syndrome in the dog breed Gammel Dansk Hønsehund: clinical, electrophysiological, pharmacological and immunological comparison with acquired myasthenia gravis.

Authors:  A Flagstad; W Trojaborg; S Gammeltoft
Journal:  Acta Vet Scand       Date:  1989       Impact factor: 1.695

Review 7.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 8.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

9.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Authors:  Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

10.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.